Kevin Howe - Biora Therapeutics Senior Operations
| BIOR Stock | USD 1.93 0.14 7.82% |
Executive
Kevin Howe is Senior Operations of Biora Therapeutics
| Address | 4330 La Jolla Village Drive, San Diego, CA, United States, 92122 |
| Phone | 833 727 2841 |
| Web | https://www.bioratherapeutics.com |
Biora Therapeutics Management Efficiency
The company has return on total asset (ROA) of (1.2506) % which means that it has lost $1.2506 on every $100 spent on assets. This is way below average. Biora Therapeutics' management efficiency ratios could be used to measure how well Biora Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Biora Therapeutics' Return On Capital Employed is relatively stable compared to the past year. As of 11/28/2024, Return On Equity is likely to grow to 1.99, though Return On Tangible Assets are likely to grow to (4.69). At this time, Biora Therapeutics' Non Current Assets Total are relatively stable compared to the past year. As of 11/28/2024, Intangible Assets is likely to grow to about 3.8 M, while Net Tangible Assets are likely to drop (86 M).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Kimberly Davis | Zura Bio Limited | 56 | |
| Kevin CPA | Enveric Biosciences | 60 | |
| Robert Sweeney | Ocean Biomedical | 59 | |
| Daniel Trepanier | Hepion Pharmaceuticals | N/A | |
| MD FACC | ZyVersa Therapeutics | 74 | |
| Melda Oconnell | ZyVersa Therapeutics | N/A | |
| Esq CPA | Ocean Biomedical | 59 | |
| Biren Shah | Elevation Oncology | N/A | |
| Patrick Mayo | Hepion Pharmaceuticals | N/A | |
| Theresa Lowry | Zura Bio Limited | 50 | |
| Michael Howell | Zura Bio Limited | 47 | |
| Robert Yang | Elevation Oncology | N/A | |
| MD MBA | Ocean Biomedical | 59 | |
| Kiran MBBS | Zura Bio Limited | 51 | |
| John Cavan | Hepion Pharmaceuticals | 66 | |
| David Brady | Zura Bio Limited | N/A | |
| John SullivanBolyai | Hepion Pharmaceuticals | 76 | |
| Gary Whale | Zura Bio Limited | 50 | |
| Verender Badial | Zura Bio Limited | 52 | |
| Candice Masse | Elevation Oncology | N/A | |
Management Performance
| Return On Asset | -1.25 |
Biora Therapeutics Leadership Team
Elected by the shareholders, the Biora Therapeutics' board of directors comprises two types of representatives: Biora Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biora. The board's role is to monitor Biora Therapeutics' management team and ensure that shareholders' interests are well served. Biora Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biora Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eric Fox, VP Treasurer | ||
| Aditya MBA, CEO Director | ||
| Kevin Howe, Senior Operations | ||
| Sharat Singh, Head Research | ||
| Robyn Hatton, Head Resources | ||
| Paul MBA, Head Operations | ||
| Eric dEsparbes, Chief Officer | ||
| Clarke JD, General VP | ||
| George Gianakopoulos, Senior Sales | ||
| Ariella MD, Chief Officer | ||
| Troy Seelye, Chief Officer | ||
| James MBA, Head Development |
Biora Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biora Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.25 | ||||
| Operating Margin | (49.64) % | ||||
| Current Valuation | 44.55 M | ||||
| Shares Outstanding | 4.52 M | ||||
| Shares Owned By Insiders | 0.10 % | ||||
| Shares Owned By Institutions | 29.39 % | ||||
| Number Of Shares Shorted | 201.8 K | ||||
| Price To Sales | 9.41 X | ||||
| Revenue | 4 K | ||||
| Gross Profit | 1.25 M |
Pair Trading with Biora Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biora Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biora Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Biora Stock
| 0.81 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.87 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.95 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Biora Stock
| 0.91 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.81 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.63 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.59 | PHVS | Pharvaris BV | PairCorr |
| 0.39 | ESLAW | Estrella Immunopharma | PairCorr |
The ability to find closely correlated positions to Biora Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biora Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biora Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biora Therapeutics to buy it.
The correlation of Biora Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biora Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biora Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biora Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Biora Stock Analysis
When running Biora Therapeutics' price analysis, check to measure Biora Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biora Therapeutics is operating at the current time. Most of Biora Therapeutics' value examination focuses on studying past and present price action to predict the probability of Biora Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biora Therapeutics' price. Additionally, you may evaluate how the addition of Biora Therapeutics to your portfolios can decrease your overall portfolio volatility.